Want to see VERA full AI Analyst Report?

Vera Therapeutics (VERA) Price & Analysis

897 Followers

VERA Stock Chart & Stats

$35.28

$0.05(0.14%)

At close: Jul 27 4:00 PM EDT

$35.28

$0.05(0.14%)

Day’s Range― - ―

52-Week Range$21.71 - $56.05

Previous CloseN/A

Volume472.67K

Average Volume (3M)2.13M

Market Cap

$2.57B

Enterprise Value$2.66K

Total Cash (Recent Filing)$499.16M

Total Debt (Recent Filing)$75.23M

Price to Earnings (P/E)―

Beta1.19

Next Earnings

Nov 11, 2026

EPS Estimate

-1.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.86

Shares Outstanding72,063,330

10 Day Avg. Volume2,103,330

30 Day Avg. Volume2,133,509

Financial Highlights & Ratios

PEG Ratio-0.16

Price to Book (P/B)5.38

Price to Sales (P/S)0.00

P/FCF Ratio-13.46

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$77.23

Price Target Upside118.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-6.26

Revenue Forecast (FY)$24.71M

Bulls Say, Bears Say

Bulls Say

FDA Accelerated ApprovalFDA approval gives Vera an initial commercial pathway in a defined high-risk IgA nephropathy population. It validates atacicept’s clinical and regulatory profile and creates the foundation for future sales, physician adoption and broader indications.

Path Toward Full ApprovalAgreement on the revised eGFR analysis plan may accelerate the confirmatory process for atacicept. Successful results could support full approval, expand the product’s commercial durability and reduce dependence on the accelerated-approval pathway.

Modest Balance Sheet LeverageLow debt relative to equity limits direct interest and refinancing pressure while Vera funds development and commercialization. Although equity has declined through losses, modest leverage provides more flexibility than a debt-heavy structure during the transition toward product revenue.

Bears Say

No Established Product RevenueThe absence of demonstrated product revenue leaves commercial execution unproven even after accelerated approval. Vera must establish market access, prescribing demand and reimbursement while relying on a single lead program for its transition to a sustainable operating model.

Large And Rising LossesRapidly widening losses show that operating costs are increasing ahead of revenue generation. This weakens earnings visibility and means profitability depends on successful commercialization, disciplined spending and the ability to convert regulatory progress into recurring sales.

Heavy External Funding DependenceThe scale of cash burn can shorten the company’s financial runway and require additional capital before commercial cash flows mature. Future financing could dilute existing holders or constrain investment in launch activities and clinical development if funding conditions tighten.

Vera Therapeutics News

3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts

Analysts see strong momentum in some stocks this week, including Fervo Energy ($FRVO), Vera Therapeutics ($VERA), and Hut 8...

11d ago

HUT

FRVO

Vera Therapeutics price target lowered to $90 from $125 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vera Therapeutics (VERA) to $90 from $125 and keeps a...

19d ago

VERA

Vera Therapeutics price target raised to $84 from $78 at Raymond James

Raymond James analyst Ryan Deschner raised the firm’s price target on Vera Therapeutics (VERA) to $84 from $78...

25d ago

VERA

Vera Therapeutics price target lowered to $34 from $43 at Wedbush

Wedbush lowered the firm’s price target on Vera Therapeutics (VERA) to $34 from $43 and keeps a Neutral...

25d ago

VERA

Vera Therapeutics price target lowered to $66 from $70 at BofA

BofA lowered the firm’s price target on Vera Therapeutics (VERA) to $66 from $70 and keeps a Buy...

25d ago

VERA

Vera Therapeutics reports Q3 EPS ($1.52), consensus ($1.59)

“The accelerated approval and commercial launch of TRUTAKNA represent transformative milestones for Vera Therapeutics (VERA) and are the...

25d ago

VERA

Buy Rating Reiterated on Vera as Atacicept Data Strengthens Case and Shares Trade Below Unchanged $66 Price Target

Vera Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on August 14. Analyst Dina...

19d ago

VERA

Analyst Maintains Buy on Vera Therapeutics, Cutting Trutakna Price Target to $90 Amid Rising IgAN Competition

Vera Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Arthur He CFA...

24d ago

VERA

Analyst Sees Vera Well Positioned for Trutakna IgAN Launch, Sustained Uptake and Long‑Term Value Creation

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Vera Therapeutics. The associated price target...

24d ago

VERA

Analyst Reiterates Buy on Vera as Trutakna Launch and IgAN Pipeline Progress Support Maintained $90 Price Target

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Vera Therapeutics. The associated price target...

25d ago

VERA

Vera Therapeutics Announces New Chief Regulatory Officer

Vera Therapeutics ( ($VERA) ) has issued an announcement. On July 9, 2026, Vera Therapeutics announced a leadership...

2M ago

VERA

Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed

Vera Therapeutics (VERA) announced a planned transition of the chief regulatory officer position. William Turner, current chief regulatory...

2M ago

KYTX

VERA

Vera Therapeutics price target raised to $76 from $56 at Guggenheim

Guggenheim raised the firm’s price target on Vera Therapeutics (VERA) to $76 from $56 and keeps a Buy...

2M ago

VERA

Vera Therapeutics price target raised to $78 from $73 at TD Cowen

TD Cowen raised the firm’s price target on Vera Therapeutics (VERA) to $78 from $73 and keeps a...

2M ago

VERA

VERA FAQ

What was Vera Therapeutics’s price range in the past 12 months?

Vera Therapeutics lowest stock price was $21.71 and its highest was $56.05 in the past 12 months.

What is Vera Therapeutics’s market cap?

Vera Therapeutics’s market cap is $2.57B.

When is Vera Therapeutics’s upcoming earnings report date?

Vera Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 67 days.

How were Vera Therapeutics’s earnings last quarter?

Vera Therapeutics released its earnings results on Aug 10, 2026. The company reported -$1.52 earnings per share for the quarter, beating the consensus estimate of -$1.576 by $0.056.

Is Vera Therapeutics overvalued?

According to Wall Street analysts Vera Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vera Therapeutics pay dividends?

Vera Therapeutics does not currently pay dividends.

What is Vera Therapeutics’s EPS estimate?

Vera Therapeutics’s EPS estimate is -1.61.

How many shares outstanding does Vera Therapeutics have?

Vera Therapeutics has 72,063,330 shares outstanding.

What happened to Vera Therapeutics’s price movement after its last earnings report?

Vera Therapeutics reported an EPS of -$1.52 in its last earnings report, beating expectations of -$1.576. Following the earnings report the stock price went down -4.085%.

Which hedge fund is a major shareholder of Vera Therapeutics?

Currently, no hedge funds are holding shares in VERA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vera Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-7.87%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Vera Therapeutics

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Vera Therapeutics (VERA) Earnings & Revenues

Historic Earnings Reports

VERA Stock 12 Month Forecast

Average Price Target

$77.23

▲(118.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","60":"$60","101":"$101","39.5":"$39.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.23076923076923,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,39.5,60,80.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.1,37.323076923076925,42.54615384615385,47.769230769230774,52.99230769230769,58.21538461538462,63.43846153846154,68.66153846153847,73.88461538461539,79.1076923076923,84.33076923076923,89.55384615384617,94.77692307692308,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.1,35.57159763313609,39.04319526627219,42.514792899408285,45.98639053254438,49.457988165680476,52.92958579881657,56.40118343195266,59.87278106508876,63.34437869822485,66.81597633136094,70.28757396449703,73.75917159763313,{"y":77.23076923076923,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.1,32.246153846153845,32.392307692307696,32.53846153846154,32.684615384615384,32.830769230769235,32.97692307692308,33.12307692307692,33.26923076923077,33.41538461538462,33.56153846153846,33.707692307692305,33.853846153846156,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.28,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >